AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04067726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Baseline and 12 months
Study NCT04067726 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Baseline and 12 months
Study NCT04532619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathering Through Change
Description: Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
Study NCT03643133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide
Description: 48 doses overall over 36 weeks
Study NCT03643133 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EI or M-API regimen depending on patient age
Description: M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days
Study NCT01628120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Subcutaneous(SC) injection
Study NCT03902275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantra-Algorithm
Description: Hemotherapy based on Quantra-Algorithm
Study NCT03643133 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EI or M-API regimen depending on patient age
Description: M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days
Study NCT02529449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02529449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study NCT02737800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrioma aspiration
Description: Transvaginal ultrasound guided aspiration
Study NCT02737800 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: endometrioma aspiration
Description: Transvaginal ultrasound guided aspiration
Study NCT02737800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh agonist ( Decapeptyl )
Description: 3 monthly doses of Decapeptyl 7.5mg intramuscular
Study NCT03902275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ROTEM-Algorithm
Description: Hemotherapy based on Basic-Algorithm
Study NCT02737800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard long stimulation protocol
Description: Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.
Study NCT02737800 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard long stimulation protocol
Description: Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.
Study NCT01479452 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bariatric surgery
Description: Gastric banding, vertical banded gastroplasty, gastric bypass
Study NCT01479452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Non-surgical obesity treatment
Study NCT01927757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection
Study NCT02497287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine (Intranasal Spray)
Description: Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
Study NCT02497287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study NCT02497287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral Antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
Study NCT02497287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study NCT02497287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
Study NCT01927757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background methotrexate at least 15 mg weekly
Study NCT02110771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAÏA - facial affect recognition targeted
Description: 2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage.
Study NCT02110771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOS - attentional process targeted
Description: 2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
Study NCT01455558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal
Description: Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart
Study NCT02221401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Study NCT02221401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study NCT02221401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01946022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: randomization between the two GnRH analogues (agonist and antagonist)
Study NCT03657498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined orthodontic-orthognathic treatment
Description: combined treatment including orthodontics and orthognathic surgery
Study NCT03657498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard orthodontic treatment
Description: treatment with standard orthodontic procedures
Study NCT02357030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl-P plus GWI Nutrient Formula
Description: Week 1:~* One tablet of Methyl-P (5mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~* Two tablets of Methyl-P (10mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily
Study NCT01519609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bowel prep before endoscopy
Description: bowel prep before colonoscopy
Study NCT01830114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web app
Description: The Checkup and Choices web application
Study NCT03595826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurostimulant pharmaceutical drugs
Description: The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
Study NCT01005836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for youth anxiety
Study NCT01005836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual clinic care
Study NCT01005836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for youth depression
Study NCT03943251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995PA•H2O tablet
Description: 2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
Study NCT03943251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
Study NCT02887209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Cognitive behavioural therapy for insomnia (CBT-I; Edinger \& Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered.
Study NCT03019510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: No exercise will be done on the day of the study night to be tested
Study NCT03019510 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No exercise
Description: No exercise will be done on the day of the study night to be tested
Study NCT03019510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning exercise
Description: Early morning exercise will be done on the day of the study night to be tested
Study NCT03019510 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Morning exercise
Description: Early morning exercise will be done on the day of the study night to be tested
Study NCT03019510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evening exercise
Description: Evening exercise will be done on the day of the study night to be tested
Study NCT02437214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of music for anxiety in children
Description: The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song.
Study NCT03019510 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Evening exercise
Description: Evening exercise will be done on the day of the study night to be tested
Study NCT02330432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w
Description: Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
Study NCT02330432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best standard care
Description: Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
Study NCT02330432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best standard care
Description: Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
Study NCT03166943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systolic function by echocardiography
Description: Echocardiography for evaluation of systolic function:~* by biplane Simpson's method.~* by speckle tracking:
Study NCT03166943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diastolic function by echocardiography
Description: Echocardiography for evaluation of diastolic function:~* Left atrial Volume~* Mitral Inflow Patterns~  * Pulsed wave Doppler~ * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~* Tissue Doppler Annular Early and Late Diastolic Velocities~  * Pulsed wave tissue doppler imaging~ * Primary measurements include the systolic , early diastolic, and late diastolic velocities.
Study NCT02690025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP1848
Study NCT04246216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Stimulation
Description: Experimental: Percutaneous Electrical Nerve Stimulation The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
Study NCT04246216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surgery of the carpal tunnel
Description: The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
Study NCT00568061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric oxide for inhalation
Study NCT00568061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas (placebo) for inhalation
Study NCT02154503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: topical 5% Minoxidil (Microneedling)
Study NCT02973724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
Study NCT02243280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet
Study NCT02243280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet
Study NCT04149925 — intervention group
Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler
Study NCT04149925 — intervention group
Intervention type: DEVICE
Intervention: Echelon Flex Powered Stapler
Description: Surgery with Echelon Flex Powered Stapler
Study NCT03834233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
Study NCT01003457 — intervention group
Intervention type: OTHER
Intervention: ultrasonography
Description: transvaginal ultrasonography of bladder wall thickness
Study NCT01590290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: financial compensation
Description: financial monetary reimbursement
Study NCT04332523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
Study NCT02973724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Description: Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
Study NCT05140746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
Description: Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.
Study NCT02662725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPILIMUMAB
Study NCT02662725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Study NCT00800969 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FDG-PET-CT
Description: Radiologic standard procedure
Study NCT00317135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
Study NCT00317135 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix/Hiberix vaccine
Description: The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
Study NCT00828542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonogestrel implant
Description: Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
Study NCT00828542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot medroxyprogesterone acetate
Description: 150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
Study NCT03627130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate
Description: Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
Study NCT03627130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride
Description: Potassium Chloride capsules for 5 days
Study NCT03511911 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
Study NCT00935649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PinPointe FootLaser
Description: Medical laser
Study NCT02829411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workforce Readiness Program
Description: job readiness workshops, organized into ten daily sessions over two weeks.